EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial

Takao Hirano iD, Toshinori Murata, Shintaro Nakao, Masahiko Shimura, Miho Nozaki, Kiyoshi Suzuma, Taiji Nagaoka, Masahiko Sugimoto, Yoshihiro Takamura, Tomoaki Murakami, Keisuke Iwasaki, Jun Tsujimura und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311484 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Takao Hirano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shinshu University School of Medicine, Nagano, Japan. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Macular Edema. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In patients with diabetic macular edema (DME) from YOSEMITE/RHINE, dual angiopoietin-2/vascular endothelial growth factor-A (VEGF-A) inhibition with faricimab resulted in visual/anatomic improvements with extended dosing. The SWAN trial (jRCTs031230213) will assess the efficacy, durability, and safety of faricimab during the treatment maintenance phase in patients with DME using a treat-and-extend (T&E)-based regimen adapted to clinical practice and the characteristics of patients achieving extended dosing intervals.

Methods

SWAN is a 2-year, open-label, single-arm, interventional, multicenter trial enrolling adults with center-involving DME. All patients will receive three initial faricimab 6.0 mg doses every 4 weeks (Q4W). From week 12 onwards, in patients without active DME, dosing intervals will be extended in 8-week increments up to Q24W. In contrast, patients with active DME (central subfield thickness [CST] >325 μm and intraretinal fluid [IRF] or subretinal fluid [SRF] resulting in vision loss/disease aggravation) will receive a dose within a day and the dosing interval will be shortened by 4 weeks to a minimum of Q8W relative to the previous dosing interval. Recruitment commenced in August 2023 across a planned 16 sites in Japan.

Results

The primary endpoint is change in best-corrected visual acuity (BCVA) from baseline at 1 year (averaged over weeks 52, 56, and 60). Key secondary endpoints include: change from baseline in BCVA, CST, and National Eye Institute Visual Function Questionnaire scores over time; proportion of patients with BCVA (decimal visual acuity) ≥0.5, ≥0.7, ≥1.0, or ≤0.1; proportion of patients with absence of DME, and IRF and/or SRF over time. Safety endpoints include incidence/severity of ocular/nonocular adverse events.

Conclusions

The SWAN trial is expected to provide evidence to support individualized faricimab dosing regimens, with the potential to reduce the burden of frequent treatments on patients, caregivers, and healthcare systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyMacular EdemaAdultAgedFemaleHumansMaleMiddle AgedAngiogenesis InhibitorsAngiopoietin-2Antibodies, Monoclonal, HumanizedTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityMulticenter Studies as Topic

Substanzen

Angiogenesis InhibitorsAngiopoietin-2ANGPT2 protein, humanAntibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Shinshu University School of Medicine, Nagano, Japan.
  • Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan.
  • Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Department of Ophthalmology, Laser Eye Center, Nagoya City University East Medical Center, Aichi, Japan.
  • Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan.
  • Department of Ophthalmology, Asahikawa Medical University, Hokkaido, Japan.

ORCID-Profile: Takao Hirano

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Hirano, T., Murata, T., Nakao, S., Shimura, M., Nozaki, M., Suzuma, K., Nagaoka, T., Sugimoto, M., Takamura, Y., Murakami, T., Iwasaki, K., Tsujimura, J., & Yoshida, S. (2024). Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0311484

Vancouver

Hirano T, Murata T, Nakao S, Shimura M, Nozaki M, Suzuma K, et al. Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0311484

BibTeX
@article{Hirano2024,
  author = {Hirano, Takao and Murata, Toshinori and Nakao, Shintaro and Shimura, Masahiko and Nozaki, Miho and Suzuma, Kiyoshi and Nagaoka, Taiji and Sugimoto, Masahiko and Takamura, Yoshihiro and Murakami, Tomoaki and Iwasaki, Keisuke and Tsujimura, Jun and Yoshida, Shigeo},
  title = {Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311484}
}
Kostenlos starten →